Docket No.

279681US0PCT

TENT AND TRADEMARK OFFICE IN THE UNITED

IN RE APPLICATION OF:

Luca BARBERO, et al.

SERIAL NO:

10/554,372

GAU:

FILED:

October 25, 2005

EXAMINER:

FOR:

BETA-AMYLOID INHIBITORS AND USE THEREOF

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

COMMISSIONER FOR PATENTS ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

REFERENCES

- The applicant(s) wish to make of record the references listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

- Attached is a list of applicant's pending application(s), published application(s) or issued patent(s) which may be related to the present application. In accordance with the waiver of 37 CFR 1.98 dated September 21, 2004, copies of the cited pending applications are not provided. Cited published and/or issued patents, if any, are listed on the attached PTO form 1449.
- A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

- ☐ Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- □ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, P.C.

Norman F. Oblon

Registration No. 24,618

Customer Number

Tel. (703) 413-3000 Fax. (703) 413-2220 (OSMMN 05/03)

Surinder Sachar

Registration No. 34,423

JAN 2 5 2006 W

SHEET 1 OF 2

SERIAL NO. ATTY DOCKET NO. U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE Form PTO 1449 (Modified) 10/554,372 279681US0PCT **APPLICANT** LIST OF REFERENCES CITED BY APPLICANT Luca BARBERO, et al. **FILING DATE GROUP** October 25, 2005 **U.S. PATENT DOCUMENTS** FILING DATE SUB **EXAMINER** DOCUMENT CLASS DATE NAME IF APPROPRIATE INITIAL NUMBER **CLASS** 6 399 584 06/04/02 ARPIN et al. AA 11/20/01 FINDEIS et al. AB 6 319 498 **FOREIGN PATENT DOCUMENTS** TRANSLATION DOCUMENT COUNTRY DATE NUMBER NO NO 10/26/00 wo AC 00/63246 NO AΠ 01/07473 02/01/01 WO NO wo 05/25/00 ΑE 00/29427 NO WO ΑF 02/062989 08/15/02 NO 2 829 940 03/28/03 FR AG NO 02/10195 02/07/02 WO AH NO wo ΑI 96/39834 12/19/96 NO 98/38861 09/11/98 WO A.I NO WO (with English abstract) ΑK 01/09170 02/08/01 NO 01/34631 05/17/01 WO AL OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.) CLELAND et al. "Emerging protein delivery methods", Current Opinion in Biotechnology, vol. 12, pages 212-219 ΑM 2001 DEROSSI et al. "The Third Helix of the Antennapedia Homedomain Translocates through Biological Membranes", The Journal of Biological Chemistry, vol. 269, no. 14, pages 10444-10450 DOUGHERTY. "Unnatural amino acids as probes of protein structure and function", Current Opinion in Chemical Biology, vol. 4, pages 645-652 AO 2000 GOLEBIOWSKI et al. "High-throughput organic synthesis of peptide mimetics", Current Opinion in Drug Discovery and Development, vol. 4, no. 4, pages 428-434 HARDY et al. "The Amyloid Hypothesis of Alzheimer's Disease: Progress and Problems on the Road to Therapeutics", Science, vol. 297, pages 353-356 AΩ 2002 HARPER et al. "Models of Amyloid Seeding in Alzheimer's Disease and Scrapie: Mechanistic Truths and Physiological Consequences of the Time-Dependent Solubility of Amyloid Proteins", Annu. Rev. Biochem., vol. 66, pages 385-407 AR 1997 JORDAN. "Chronic Traumatic Brain Injury Associated with Boxing", Seminars in Neurology, vol. 20, no. 2, pages 179-185 AS 2000 KIM et al. "A Merger of Rational Drug Design and Combinatorial Chemistry: Development and Application of Peptide AT Secondary Structure Mimetics", Combinatorial Chemistry & High Throughput Screening, vol. 3, pages 167-183 LEVINE. "Thioflavine T interaction with synthetic Alzheimer's disease betaamyloid peptides: Detection of amyloid aggregation in solution", Protein Additional References sheet(s) attached ΑU Science, vol. 2, pages 404-410 1993 **Date Considered** Examiner *Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in

conformance and not considered. Include copy of this form with next communication to applicant.

SHEET 2 OF 2

ATTY DOCKET NO. SERIAL NO. U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE orm PTO 1449 (Modified) 279681US0PCT 10/554,372 **APPLICANT** LIST OF REFERENCES CITED BY APPLICANT Luca BARBERO, et al. GROUP **FILING DATE** October 25, 2005 OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.) LEVY et al. "Mutation of the Alzheimer's Disease Amyloid Gene in Hereditary Cerebral Hemorrhage, Dutch Type", Science, vol. 248, pages 1124-1126 1990 LUO et al. "Novel biomaterials for drug delivery", Expert Opin. Ther. Patents, vol. 11, no. 9, pages 1395-1410 2001 LOWE et al. "Structure -Function Relationships for Inhibitors of beta-Amyloid Toxicity Containing the Recognition Sequence KLVFF", Biochemistry, vol. 40, pages 7882-7889 2001 MANN. "Alzheimer's disease and Down's syndrome", Histopathology, vol. 13, pages 125-137 1988 AY MAURY. "Molecular Pathogenesis of beta-Amyloidosis in Alzheimer's Disease and Other Cerebral Amyloidoses", Laboratory Investigation", vol. 72, no. 1, pages 4-16 ΑZ 1995 ROUSSELLE et al. "New Advances in the Transport of Doxorubicin through the Blood-Brain Barrier by a Peptide Vector-Mediated Strategy", Molecular Pharmacology, vol. 57, pages 679-686 SELKOE. "Alzheimer's Disease: Genotypes, Phenotype, and Treatments", Science, vol. 275, pages 630-631 AAB SOTO et al. "The alpha-Helical to beta-Strand Transition in the Amino-terminal Fragment of the Amyloid beta-Peptide Modulates Amyloid Formation", The Journal of Biological Chemistry, vol. 270, no. 7, pages 3063-3067 AAC SOTO et al. "Beta-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: Implications for Alzheimer's therapy", Nature Medicine, vol. 4, no. 7, pages 822-826 AAD 1998 SOTO. "Alzheimer's and prion disease as disorders of protein conformation: implications for the design of novel therapeutic approaches", J. Mol. Med., vol. 77, pages 412-418 AAE TALAGA. "Beta-Amyloid Aggregation Inhibitors for the Treatment of Alzheimer's Disease: Dream or Reality?", Mini Reviews in Medicinal Chemistry, vol. 1, pages 175-186 AAF 2001 VILLAIN et al. "Covalent capture: a new tool for the purification of synthetic and recombinant polypeptides", Chemistry and Biology, vol. 8, pages 673-679 AAG 2001 XIA. "Amyloid inhibitors and Alzheimer's disease", Current Opinion in Investigational Drugs, vol. 4, no. 1, pages 55-59 2003 AAH YANKNER. "Mechanisms of Neuronal Degeneration in Alzheimer's Disease", Neuron, vol. 16, page 921-932 1996 AAI AAJ **AAK** AAL **Date Considered** Examiner *Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in

conformance and not considered. Include copy of this form with next communication to applicant.



U.S. PCT Application Serial No: 10/554,372

Filed: October 25, 2005 Luca BARBERO, et al.

Docket No. 279681US0PCT

STATEMENT OF RELEVANCY

- 1) References AA, AC-AG have been cited in the International Search Report. A copy of these references is being submitted herewith.
- 2) References have been cited in the corresponding copy of these references is being submitted herewith.
- 3) References AB, AH-AAI are discussed in the specification. A copy of these references is being submitted herewith.
- 4) References are additional prior art known to Applicant. A copy of these references is being submitted herewith.